-+ 0.00%
-+ 0.00%
-+ 0.00%

Palisade Bio Announces It Will Present AI-Driven Approach To IBD Heterogeneity And Efficacy At 3rd Annual Precision Medicine In Inflammatory Bowel Disease Summit May13-15, 2025 In Boston, MA

Benzinga·05/01/2025 12:36:15
Listen to the news

Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to give an oral presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit being held May 13–15, 2025 in Boston, MA.

Details of the oral presentation are as follows:

Session: Advancing AI-Driven Diagnostics & Enhancing Patient Monitoring to Personalize Treatment Decisions & Improve Long-Term Patient Outcomes

Title: Improving Patient Subtyping with AI-Driven Insights to Unlock Better Insights into IBD Heterogeneity & Smash the Efficacy Ceiling

Presenter: Joerg Heyer, Ph.D., Head of Translational Science and Medicine at Palisade

Session Date & Time: May 13, 2025 from 9:30 AM to 10:00 AM ET

The 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit provides a unique platform to explore groundbreaking advancements, refine precision medicine strategies, and drive the development of transformative treatments - ensuring the right drug reaches the right patient, at the right time. For more information about the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit, please visit the summit website.